Fisher Asset Management LLC Lowers Position in BioCryst Pharmaceuticals, Inc. $BCRX

Fisher Asset Management LLC trimmed its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 6.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,467,567 shares of the biotechnology company’s stock after selling 165,129 shares during the quarter. Fisher Asset Management LLC’s holdings in BioCryst Pharmaceuticals were worth $19,247,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of BCRX. Larson Financial Group LLC grew its holdings in BioCryst Pharmaceuticals by 1,188.0% in the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 3,267 shares during the period. Focus Partners Wealth purchased a new stake in BioCryst Pharmaceuticals in the third quarter valued at approximately $77,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in BioCryst Pharmaceuticals by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 2,115 shares during the period. Vestmark Advisory Solutions Inc. purchased a new stake in BioCryst Pharmaceuticals in the third quarter valued at approximately $81,000. Finally, Envestnet Portfolio Solutions Inc. acquired a new stake in BioCryst Pharmaceuticals during the 4th quarter worth approximately $81,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently issued reports on BCRX shares. Needham & Company LLC dropped their target price on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Royal Bank Of Canada dropped their target price on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. Wedbush dropped their target price on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Citizens Jmp increased their target price on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 7th. Finally, Weiss Ratings raised shares of BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research report on Wednesday, March 4th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $20.70.

BioCryst Pharmaceuticals Trading Up 7.7%

BioCryst Pharmaceuticals stock opened at $9.12 on Thursday. The stock has a market cap of $2.32 billion, a P/E ratio of -5.12 and a beta of 0.57. The stock has a 50 day moving average of $9.16 and a 200-day moving average of $7.99. BioCryst Pharmaceuticals, Inc. has a 52 week low of $6.00 and a 52 week high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing the consensus estimate of $0.06 by ($3.04). The business had revenue of $156.41 million for the quarter, compared to analysts’ expectations of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.20 earnings per share. As a group, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.66 earnings per share for the current fiscal year.

Insider Activity at BioCryst Pharmaceuticals

In other news, insider Alane P. Barnes sold 150,000 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $9.15, for a total transaction of $1,372,500.00. Following the completion of the transaction, the insider directly owned 400,703 shares in the company, valued at approximately $3,666,432.45. This represents a 27.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 5.10% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.